PlexBio Co., Ltd. (TPEX:6572)

Market Cap	805.36M
Revenue (ttm)	153.06M
Net Income (ttm)	-64.51M
Shares Out	103.65M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,372
Average Volume	220,988
Open	7.77
Previous Close	7.77
Day's Range	7.42 - 7.90
52-Week Range	7.20 - 12.70
Beta	0.11
RSI	44.63
Earnings Date	Apr 27, 2026

About PlexBio

PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation extraction kits; IntelliPlex platform that is designed for pCode technology with for sample-to-answer multiplexing assays; oncology kits for lung cancer and mutation detection, as well as rearrangements; IntelliPlex SARS-CoV-2 detection test kits/flu kits and IntelliPlex SARS-CoV-2 variant analysis kits; and pCode coupling buffer sets. PlexBio Co., Ltd. was f...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2009
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6572

Financial Performance

In 2024, PlexBio's revenue was 128.06 million, a decrease of -23.40% compared to the previous year's 167.18 million. Losses were -61.63 million, 5.30% more than in 2023.